Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg Twice Daily (BID) in Combination With Standard of Care in Patients With Active Lupus Nephritis

Next Previous
Trial Profile

An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg Twice Daily (BID) in Combination With Standard of Care in Patients With Active Lupus Nephritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voclosporin (Primary) ; Corticosteroids; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Acronyms AURION
  • Sponsors Aurinia Pharmaceuticals

Most Recent Events

  • 17 Mar 2021 Number of Participants With Reduction or Normalization of Anti ds DNA, C3 and C4, have been introduced as new primary end-points in addition to the existing one (Urine Protein/Creatinine Ratio (UPCR)).
  • 18 Sep 2017 Status changed from active, no longer recruiting to completed.
  • 27 Mar 2017 Results at week 48 published in an Aurinia Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top